# US 2021/0171546 A1 · Methods of preparing cytotoxic benzodiazepine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171546 A1
- Document ID: US20210171546A1
- Status: Published application
- Kind: A1
- Application number: 16/991,700
- Filed: 2020-08-12
- Published: 2021-06-10
- Earliest claimed: 2015-07-21
- Assignees: ImmunoGen, Inc.
- Applicants: Immunogen, Inc.
- Inventors: Baudouin Gérard; Manami Shizuka; Michael Louis Miller; Richard A. Silva
- Web page: https://patentgrep.com/patent/US20210171546A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P 35/00: Antineoplastic agents
- C07C 303/28: by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
- C07D 487/04: Ortho-condensed systems
- C07K 5/0804: {and aliphatic}
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

A method of preparing a compound of formula (20A):
or a salt thereof, said method comprising the step of reacting a brominating or iodinating reagent with a compound of formula (14A):
or a salt there of, wherein
X3 is —Cl; and
X5 is —Br or —I.

### Claim 27 (depends on 26)

The method of claim 26, wherein the brominating or iodinating reagent is bromine, hydrobromic acid, carbon tetrabromide, phosphorus tribromide, potassium bromide, hydroiodic acid, iodine, carbon tetraiodide, phosphorus triiodide, sodium iodide, or potassium iodide.

### Claim 28 (depends on 26)

The method of claim 26, further comprising the step of reacting the compound of formula (20A) or a salt hereof with a monomer compound of formula (b1):
to form a compound of formula (16A):
or a salt thereof.

### Claim 29 (depends on 28)

The method of claim 28, wherein the compound of formula (20A) is reacted with the monomer compound of formula (b1) in the presence of a base.

### Claim 30 (depends on 29)

The method of claim 29, wherein the base is sodium carbonate, potassium carbonate, cesium carbonate, sodium hydride, or potassium hydride.

### Claim 31 (depends on 30)

The method of claim 30, wherein the base is potassium carbonate.

### Claim 32 (depends on 28)

The method of claim 28, wherein the compound of formula (20A) is reacted with a monomer compound of formula (b1) in the presence of a polar aprotic solvent.

### Claim 33 (depends on 32)

The method of claim 32, wherein the polar aprotic solvent is dimethylacetamide.

### Claim 34 (depends on 26)

The method of claim 26, further comprising the step of reacting the compound of formula (20A) or a salt thereof with a monomer compound of formula (d1):
to form a compound of formula (17A):
or a salt thereof, wherein P3 is H or an amine protecting group.

### Claim 35 (depends on 34)

The method of claim 34, wherein the compound of formula (20A) is reacted with the monomer compound of formula (d1) in the presence of a base.

### Claim 36 (depends on 35)

The method of claim 35, wherein the base is sodium carbonate, potassium carbonate, cesium carbonate, sodium hydride, or potassium hydride.

### Claim 37 (depends on 36)

The method of claim 36, wherein the base is potassium carbonate.

### Claim 38 (depends on 34)

The method of claim 34, wherein the compound of formula (20A) is reacted with the monomer compound of formula (d1), wherein P3 is H, to form a compound of formula (17A′):

### Claim 39 (depends on 34)

The method of claim 34, wherein P3 is an amine protecting group and the method further comprises the step of reacting the compound of formula (17A) with an amine deprotecting reagent to form a compound of formula (17A′):

### Claim 40 (depends on 39)

The method of claim 39, wherein the amine deprotecting reagent is selected from the group consisting of tetra-n-butylammonium fluoride, acetic acid, hydrogen fluoride pyridine, cesium fluoride, piperidine, morpholine, and trifluroacetic acid.

### Claim 41 (depends on 26)

The method of claim 26, further comprising the steps of:
(i) reacting the compound of formula (20A) or a salt hereof with a monomer compound of formula (b1):
to form a compound of formula (16A):
or a salt thereof;
(ii) reacting the compound of formula of (16A) or a salt thereof with a monomer compound of formula (d1):
to form a compound of formula (18A):
or a pharmaceutically acceptable salt thereof, wherein:
P3 is H or an amine protecting group.

### Claim 42 (depends on 41)

The method of claim 41, wherein the compound of formula (16A) is reacted with the monomer compound of formula (d1), wherein P3 is H, to form a compound of formula (IA):

### Claim 43 (depends on 41)

The method of claim 41, wherein P3 is an amine protecting group and the method further comprise reacting the compound of formula (18A) with an amine deprotecting reagent to form a compound of formula (IA):

### Claim 44

A method of preparing a compound of formula (18A):
or a pharmaceutically acceptable salt thereof, comprising the steps of:
(1) reacting a brominating or iodinating reagent with a compound of formula (14A):
or a salt there of, to form a compound of formula (20A):
or a salt thereof;
(2) reacting the compound of formula (20A) or a salt thereof with a monomer compound of formula (d1):
to form a compound of formula (17A):
or a salt thereof;
(3) reacting the compound of formula of (17A) or a salt thereof with a monomer compound of formula (b1):
to form the compound of formula (18A) or a pharmaceutically acceptable salt thereof, wherein:
X3 is —Cl;
X5 is —Br or —I; and
P3 is H or an amine protecting group.

### Claim 45

A method of preparing a compound of formula (IA):
or a pharmaceutically acceptable salt thereof, comprising the steps of:
(1) reacting a brominating or iodinating reagent with a compound of formula (14A):
or a salt thereof, to form a compound of formula (20A):
or a salt thereof;
(2) reacting the compound of formula (20A) or a salt thereof with a monomer compound of formula (b1):
to form a compound of formula (16A):
or a salt thereof;
(3) reacting the compound of formula (16A) or a salt thereof with an imine reducing agent to form a compound of formula (17A′):
or a salt thereof;
(4) reacting the compound of (17A′) or a salt thereof with a monomer of formula (b1):
to form the compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein:
X3 is —Cl; and
X5 is —Br or —I.
